Klinische Ergebnisse von Patientinnen mit primärem und sekundärem epithelialem Ovarialkarzinom im Krankenhaus im Friedrichshain von 1992 bis 1998Beata Magdalena Morys34567192102.12.211365#249365#246122.313142.4152.52.5.1162.5.22.6172.7318599#1903.119203.221605#4503.322234244.1471#237471#23725466#2394.2264.2.1509#237274.2.228524#275521#34929304.2.331324.2.43334354.2.53637384.3394.3.14041468#23542468#23443444546474849513#3414.3.25051524.3.34.4534.4.1503#2384.4.254475#2384.4.355552#3694.55657582#3814.658473#23459474#256471#23260471#237474#2376162541#364634.76465541#364664.84.967508#37068508#3704.9.169506#3644.9.270506#364506#3644.9.371506#3644.9.472506#3644.9.5542#370734.9.6506#3644.9.774506#3644.9.875508#3704.9.976533#3474.9.1077541#36978540#3644.9.1179808182452#36483451#364451#36484451#364451#36485451#3645865.1875.288895.3905.4915.592935.69495965.79798995.81001015.91021031041055.101065.111076108109110 Literatur111112113114115116117118119120121 Danksagung122 Erklärung an Eides statt123deInhaltsverzeichnisHilfe Literatur [ACOG`02]ACOG Committee on Gynecologic Practice: „The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer”, Gynecol Oncol 87, S. 237 - 239, 2002 [Akahira`01]Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, Shiromizu K, Kuzuya K, Kamura T, Kikuchi Y, Kodama S, Yamamoto K, Sato S: „Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study“, Gynecol Oncol 81, S. 398 - 403, 2001 [Allen`99]Allen DG, Coulter J: „Survival of patients with epithelial ovarian cancer and the effect of lymphadenectomy in those with stage 3 disease“, Aust NZ J Obstet Gynecol 39, S. 420 - 424, 1999 [Berek`99]Berek JS, Bertelsen K, du Bois A, Brady MF, et al.: „Advanced epithelial ovarian cancer: 1998 consensus statements”, Annals of Oncology 10 (Suppl. 1), S. 87 - 92, 1999 [du Bois`97]du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C: „Carboplatin Plus Paclitaxel as First-Line Chemotherapy in Previously Untreated Advanced Ovarian Cancer“, Seminars in Oncology 24 (Suppl. 11), S. 28 - 33, 1997 [du Bois`01]du Bois A, Pfisterer J, Kellermann L, Kreienberg R: „Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: Welchen Einfluss hat die Teilname an klinischen Studien?“, Geburtshilfe Frauenheilkunde 61, S. 863 - 871, 2001 [du Bois`03]du Bois A: „Primäre Chemotherapie des Ovarialkarzinoms“ in du Bois, Lichtenegger, von Minckwitz, Wallwiener „Taxol-Therapie in der gynäkologischen Onkologie“, W. Zuckschwerdt Verlag München Wien New York, S. 1 – 12, 2003 [du Bois`03-1]du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S et al.: „A randomized clinical trial of cisplatin / paclitaxel versus carboplatin / paclitaxel as first-line treatment of ovarian cancer“, J Natl Cancer Inst 95, S. 1320 – 1329, 2003 [Bridgewater`99]Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ: „Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or Paclitaxel“, Journal of Clinical Oncology 17, S. 501 - 508, 1999 [Bristow`02]Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: „Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta – analysis”, J Clin Oncol 20, S. 1248-1259, 2002 [Bruchim`01]Bruchim I, Altaras M, Fishman A: „Age Contrasts in Clinical Characteristics and Pattern of Care in Patients with Epithelial Ovarian Cancer“,Gynecologic Oncology 86, S. 274 - 278, 2001 [Bühl`99]Bühl A, Zöfel P: „SPSS Version 8 Einführung in die moderne Datenanalyse unter Windows“, Bonn: Addison-Wesley-Longman, 1999 [Carnino`97]Carnino F, Fuda G, Ciccone G, Iskra L, Guercio E, Dadone D, Conte PF: „Significance of lymph node sampling in epithelial carcinoma of the ovary“, Gynecol Oncol 65, S. 467 -472, 1997 [Cass`01]Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, Lagasse LD, Karlan BY: „Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas“, Gynecolgic Oncology 80, S. 56 - 61, 2001 [Chi`99]Chi DS, Venkatraman ES, Masson V, Hoskins WJ: „The Ability of Preoperative Serum CA-125 to Predict Optimal Primary Tumor Cytoreduction in Stage III Epithelial Ovarian Carcinoma”, Gynecologic Oncology 77, S. 227 - 231, 2000 [Chi‘01]Chi D, Liao J, Leon L, Venkatraman E, Hensley M, Bhaskaran D, Hoskins W: „Identification of Prognostic Factors in Advanced Epithelial Ovarian Carcinoma“, Gynecologic Oncology 82, S. 532 - 537, 2001 [Cooper`02]Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE: „Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer”, Obstet Gynecol 100, S. 59 - 64, 2002 [Covens`02]Covens A, Carey M, Bryson P, Verma S, Kee Fung M, Johnston M: „Systematic Review of First-Line Chemotherapy for Newly Diagnosed Postoperative Patients with Stage II, III, or IV Epithelial Ovarian Cancer”, Gynecologic Oncology 85, S. 71 - 80, 2002 [Cox`72]Cox DR: „Regression Models and life-tables”, JR Stat Soc B 34, S. 187 – 202, 1972 [Cramer`83]Cramer DW, Welch WR, Cassells S, Scully RE: „Mumps, menarche, menopause, and ovarian cancer”, Am J Obstst Gynecol 147, S. 1-6, 1983 [Cramer`99]Cramer DW, Liberman RF, Titus-Ernstoff L, Welch WR, Greenberg ER, Baron JA, Harlow BL: „Genital talc exposure and risk of ovarian cancer”, Int J Cancer 81, S. 351 – 356, 1999 [Curtin´97]Curtin JP, Malik R, Venkatraman ES, Barakat R, Hoskins WJ: „Stage IV Ovarian Cancer: Impact of Surgical Debulking“, Gynecologic Oncology 64, S. 9 - 12, 1997 [Deutsche Krebsgesellschaft`01]Deutsche Krebsgesellschaft EV: „ Kurzgefasste Interdisziplinäre Leitlinien 2002, Diagnostik und Therapie maligner Erkrankungen, Maligne Ovarialtumoren“, W Zuckschwerdt Verlag München, S. 284 - 297, 2001 [Dittrich`96]Dittrich C: „Die medikamentöse Therapie des Ovarialkarzinoms“, Wien-Med-Wochenschr. 146, S. 23 - 33, 1996 [Eisenkop`98]Eisenkop SM, Friedman RL, Wang HJ: „Complete Cytoreductive Surgery Is Feasible and Maximizes Survival in Patients with Advanced Epithelial Ovarian Cancer: A Prospectivve Study“, Gynecologic Oncology 69, S. 103 - 108, 1998 [Eisenkop`00]Eisenkop SM, Friedman RL, Spirtos NM: „The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma”, Cancer 88, S. 144 - 153, 2000 [Eisenkop‘01]Eisenkop SM, Spirtos NM: „What Are the Current Surgical Objectives, Strategies, and Technical Capabilities of Gynecologic Oncologists Treating Advanced Epithelial Ovarian Cancer?“, Gynecologic Oncology 82, S. 489 - 497, 2001 [Eisenkop’01-1]Eisenkop SM, Spirtos NM: „Procedures Required to Accomplish Complete Cytoreduction of Ovarian Cancer: Is there a Correlation with Biological Aggressiveness and Survival?“, Gynecologic Oncology 82, S. 435 - 441, 2001 [Eisenkop`01-2]Eisenkop SM, Spirtos NM: „The clinical Signifikance of Occult Macroscopically Positive Retroperitoneal Nodes in Patients with Epithelial Ovarian Cancer”, Gynecologic Oncology 82, S. 143 - 149, 2001 [Engel`01]Engel J, Schubert-Fritschle G: „Epidemiologie“ in Kuhn: Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge“, Tumorzentrum München, S. 1 - 9, 2001 [Enomoto`03]Enomoto T, Kuragaki C, Yamasaki M, Sugita N et al.: „Is Clear Cell Carcinoma and Mucinous Carcinoma of the Ovary Sensitive to Combination Chemotherapy with Paclitaxel and Carboplatin?”, 39th ASCO Annual Meeting, Abstract: 1797, 2003 [Fathalla`71]Fathalla MF: „Incessant ovulation-a factor in ovarian neoplasia“, Lancet 2, S. 163, 1971 [Friedman`97]Friedman RL, Eisenkop SM, Wang HJ: „Second-look Laparotomy for Ovarian Cancr Provides Reliable Prognostic Information and Improves Survival“, Gynecologic Oncology 67, S. 88 - 94, 1997 [Folk`95]Folk JJ, Botsford M, Musa AG: „Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure“, Gynecol Oncol 57, S. 178 - 182, 1995 [Geisler`96]Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE: „Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma”, J Reprod Med 41, S. 140 - 142, 1996 [Geisler`96-1]Geisler JP, Wiemenn MC, Miller GA, Geisler HE: „Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage III c serous cystadenocarcinoma of the ovary”, Gynecol Oncol 60, S. 424 - 427, 1996 [Green`97]Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M, Ward B: „Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women`s Health Study Group”, Int J. Cancer 71, S. 948 - 951, 1997 [Gronlund`02]Gronlund B, Hogdall C, Hansen HH, Engelholm SA: „Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma”, Cancer 94, S. 1961 - 1967, 2002 [A`Hern`95]A`Hern RP, Gore ME: „Impact of doxorubicin on survival in advanced ovarian cancer”, J Clin Oncol 13, S. 726 - 732, 1995 [Hess`03]Hess V, A`Hern RP; Gore ME: „Relative Platinum – Resistance of Mucinous Carcinoma of the Ovary”, 39th ASCO Annual Meeting, Abstract: 1796, 2003 [Higgins`99]Higgins RV, Neumann RW, Gardner J, Hall JB: „Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin?”, Gynecol Oncol 75, S. 464 – 467, 1999 [Holschneider`00]Holschneider CH, Berek JS: „Ovarian Cancer: Epidemiology, Biology, and Prognostic Factors”, Seminars in Surgical Oncology 19, S. 3 – 10, 2000 [Horn`95]Horn IC, Fricke K, Krugmann J: „Histologische Klassifikation und morphologische Prognosefaktoren bei malignen Ovarialtumoren”, Zentralblatt für Gynäkologie 117, S. 335 - 345, 1995 [Hoskins`89]Hoskins WJ, Rubin SC, Dulaney E, Chapman D, Almadrones L, Saigo P, Markman M, Hakes T, Reichman B, Jones WB et al.: „Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma”, Gynecol Oncol 34, S. 365 - 371, 1989 [Hoskins`94]Hoskins WJ: „Epithelial Ovarian Carcinoma: Principles of Primary Surgery”, Gynecologic Oncology 55, S. 91 - 96, 1994 [Hoskins`94-1]Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS: „The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma”, Am J Obstet Gynecol 170(4), S. 974 - 980, 1994 [Husain`01]Husain A, Chi DS, Prasad M, Abu-Rustum N, Barakat RR, Brown CL, Poynor EA, Hoskins WJ, Curtin JP: „The Role of Laparoscopy in second-Look Evaluations for Ovarian Cancer”, Gynecologic Oncology 80, S. 44 - 47, 2001 [International Collaborative Ovarian Neoplasm Group`02]International Collaborative Ovarian Neoplasm Group: „Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON 3 randomised trial”, Lancet 360, S. 505 -515, 2002 [Irwin`91]Irwin KL, Weiss NS, Lee NC, Peterson HB: „Tubal sterilisation, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer“, Am J Epidemiol 134, S. 362 - 369, 1991 [Jänicke`99]Jänicke F: „Das fortgeschrittene Ovarialkarzinom“, Deutsches Ärzteblatt 96, S. 207 - 214, 1999 [Kaplan`58]Kaplan EL, Meier P: „Nonparametric estimation from incomplete observations“, J Am Statist Assoc 53, S. 457 – 481, 1958 [Kirschbaum`01]Kirschbaum M et al.: „Checkliste Gynäkologie und Geburtshilfe“, Thieme Verlag Stuttgart New York, 2001 [Kommoss`92]Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfeiderer A: „Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects”, Gynecol Oncol 47, S. 317 – 322, 1992 [Koensgen`02]Koensgen D, Sehouli J, Katsares I, Oskay G, Stengel D, Porzsolt F, Lichtenegger W: „Is quality of life (QOL) a prognostic factor in ovarian cancer?”, 38th ASCO Annual Meeting, Abstract: 2814, 2002 [Kreienberg`98]Kreienberg R: „Die operative Therapie des Ovarialkarzinoms”, Der Onkologe 4, S. 1123 - 1130, 1998 [Kristensen`97]Kristensen GB, Trope C: „Epithelial ovarian carcinoma“, Lancet 349, S. 113 - 117, 1997 [Kuhn`01]Kuhn W, Hamann U, Rehbock J, Schmalfeldt B, Schwoerer: „Operative Therapie“, in „Kuhn: Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge“, Tumorzentrum München, S. 24 - 31, 2001 [Kuhn`01-1]Kuhn W, du Bois A, Pfisterer J: „Operative Therapie des fortgeschrittenen Ovarialkarzinoms“, Der Gynäkologe 34, S. 1050 - 1057, 2001 [Lambrou`03]Lambrou NC, Bristow RE: „Ovarian cancer in elderly women [In Process Citation]”, Oncology (Huntingt) 17, discussion 1081, S. 1075- 1081, 2003 [Ledermann`03]Ledermann JA: „Randomised Trial of Paclitaxel in Combination with Platinum Chemotherapy versus Platinum-based Chemotherapy in the Teatment of Relapsed Ovarian Cancer (ICON 4 / Ovar 2.2)”, 39th ASCO Annual Meeting, Abstract: 1794, 2003 [Lichtenegger`98]Lichtenegger W, Sehouli J, Buchmann E, Karajanev C, Weidemann H: „Operative results after primary and secondary debulking-operations in advanced ovarian cancer“, J Obstet Gynaecol Res 24, S. 447 - 451, 1998 [Lichtenegger`01]Lichtenegger W, Sehouli J, Buchmann E, Weidemann H: „Das fortgeschrittene Karzinom – Möglichkeiten und Grenzen der operativen Therapie des Ovarialkarzinoms“, in Kindermann G, Dimpfl T: „Berichtsband des 53. Kongresses der DGGG“, Thieme, S. 94 - 98, 2001 [Lippman`88]Lippman SM, Alberts DS, Slymen DJ, Weiner S, Aristizabal SA, Luditch A, Davis JR, Surwit EA: „Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration”, Cancer 61, S. 2571 - 2577, 1988 [Lutz`01]Lutz L, Kuhn W, Späthe K: „Chemotherapie“, in Kuhn: „Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge“, Tumorzentrum München, S. 35 - 77, 2001 [Malkasian`84]Malkasian GD, Melton LJ, O`Brien PC, Greene MH: „Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary”, Am J Obstet Gynecol 149, S. 274 – 284, 1984 [Mantel`61]Mantel N: „Evaluation of survival data and two new rank order statistics arising in its considerations“, Cancer Chemother Rep 50, S. 163 - 170, 1966 [Marchetti`02]Marchetti M, Zambon A, Lamaina V, Spadaro M, Marchioro S: „Ultrasound as a possible screening method in ovarian cancer“, Eur J Gynaecol Oncol 23, S. 123 - 126, 2002 [Markman`92]Markman M, Reichman B, Hakes T, Lewis JL, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W: „Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer“, J Clin Oncol 10, S. 1479 - 1484, 1992 [Markman`93] Markman M, Lewis JL, Saigo P, Hakes T, Rubin S, Jones W, Reichman B, Curtin J, Barakat R, Almadrones L, Morrissey T, Hoskins W: „Impact of Age on Survival of Patients with Ovarian Cancer“, Gynecologic Oncology 49, S. 236 - 239, 1993 [Massi`96]Massi D, Susini T, Savino L, Boddi V, Amunni G, Colafranceschi M: „Epithelial ovarian tumors in the reproductive age group”, Cancer 77, S. 1131 - 1136, 1996 [McGuire`96]McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: „Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer”, N Engl J Med 334, S. 1 - 6, 1996 [McGuire`97]McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: „Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologig Oncology Group study”, Semin Oncol 24 (Suppl. 2), S. 13 - 16, 1997 [Meerpohl`97]Meerpohl HG: „Die Second-look-Operation beim Ovarialkarzinom. Ist eine Neubewertung erforderlich?”, Der Gynäkologe 30, S. 118 - 125, 1997 [Meerpohl`02]Meerpohl HG: „Primäre Therapie des Ovarialkarzinoms” in Sehouli J, Lichtenegger W: „Chemotherapien in der Gynäkologischen Onkolgie“, Akademos, S. 97 - 107, 2002 [Meier`97]Meier W: „Sinnvoller Einsatz der Tumormarker beim Ovarialkarzinom“, Der Gynäkologe 30, S. 133 - 140, 1997 [Menon`00]Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ: „Performance of ultrasound as a second line test to serum CA 125 in ovarian cancer screening“, BJOG 107, S. 165 - 169, 2000 [Miller`92]Miller DS, Spirtos NM, Ballon SC, Cox RS, Soriero OM, Teng NN: „Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer”, Cancer 69, S. 502-510, 1992 [Möbus`97]Möbus V, Volm T, Kreienberg R: „Welche Aussichten ergeben sich durch neuere Chemotherapeutika beim Ovarialkarzinom?“, Der Gynäkologe 30, S. 108 - 117, 1997 [van Nagell`00]van Nagell JR, De Priest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, Kryscio RJ: „The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer“, Gyncol Oncol 77, S. 350 - 356, 2000 [Narod`01]Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Neuhausen S: „Tubal ligation and risk of ovarian cancer in carriers of BRCA 1 or BRCA 2 mutations: a case-control study“, Lancet 357, S. 1467 - 1470, 2001 [NIH`94]NIH: „National Institutes of Health Consensus Development Conference Statement. Ovarian Cancer: Screening, Treatment, and Follow-up”, Gynecologic Oncology 55, S. 4 - 12, 1994 [Omura`91]Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC: „Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience”, J Clin Oncol 9, S. 1138 - 50, 1991 [Opri`01]Opri F: „Second-line Therapie” in Sehouli J, Lichtenegger W: „Chemotherapien in der Gynäkologischen Onkolgie“, Akademos, S. 69 - 82, 2001 [Ozols`02]Ozols RF: „Update on the management of ovarian cancer”, Cancer 8, (Suppl. 1), S. 22 - 30, 2002 [Panici`02]Panici PB, Angioli R: „Role of lymphadenectomy in ovarian cancer”, Best Pract Res Clin Obstet Gynaecol 16, S. 529 – 551, 2002 [Parker`94]Parker D, Bradley C, Bogle SM, Lay J, Masood M, Hancock AK, Naylor B, Price JJ: „Serum albumin and CA 125 are powerful predictors of survival in epithelial ovarian cancer“, Br J Obstet Gynaecol 101, S. 888 - 893, 1994 [Parmar`03]Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM et al.: „Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial”, Lancet 361, S. 2099 – 2106, 2003 [Pecorelli`01]Pecorelli S et al.: „FIGO Annual Report on the Results of Treatment in Gynecologic Cancer. FIGO Committee on Gynecologic Oncology”, Journal of Epidemiology and Biostatistics, 2001 [Pfisterer`02]Pfisterer J, du Bois A: „Das Ovarialkarzinom. Therapeutische Standards – klinische Empfehlungen“, Thieme Verlag Stuttgart New York, 2002 [Pfisterer`03]Pfisterer J: „Müssen wir den Stellenwert und Zeitpunkt der Operation beim Ovarialkarzinom neu definieren?“, in du Bois, Lichtenegger, von Minckwitz, Wallwiener: „Taxol-Therapie in der gynäkologischen Onkologie“, W. Zuckschwerdt Verlag München Wien New York, S. 13 – 21, 2003 [Piccart`00]Piccart MJ, du Bois A, Gore ME, Pecorelli S, Pujade-Lauraine E: „A new standard of care for treatment of ovarian cancer“, European Journal of Cancer 36, S. 10 - 12, 2000 [Piccart`00-1]Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C et al.: „Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in womaen with advanced epithelial ovarian cancer: three-year results”, J Natl Cancer Inst 92, S. 699 - 708, 2000 [De Priest`94]De Priest, Varner E, Powell J, Fried A, Puls L, Higgins R, Shenson D, Kryscio R, Hunter JE, Andrews SJ: „The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation”, Gynecol Oncol 55, S. 174 - 178, 1994 [Pschyrembel`94]Pschyrembel W, Strauss G, Petri E: „Ginekologia praktyczna“, Wydawnictwo Lekarskie PZWL, 1994 [Puls`96]Puls LE, Duniho T, Hunter JE, Kryscio R, Blackhurst D, Gallion H: „The Prognostic Implication of Ascites in Advanced-Stage Ovarian Cancer”, Gynecologic Oncology 61, S. 109 - 112, 1996 [Quade`02]Quade G: „Prevention of ovarian cancer”, University of Bonn, Medical Center, 2002 [Rahaman`02]Rahaman J, Cohen C: „Impact of aszites on survival in advanced ovarian cancer” 38th ASCO Annual Meeting, Abstract: 837, 2002 [Rakar`90]Rakar S, Kovacic J, Cavic M, Lukanovic A, Mozina A: „Prognostic factors in ovarian cancer” , Eur J Gynecol Oncol 11(3), S. 171 - 173, 1990 [di Re`96]di Re F, Baiocchi G, Fontanelli R, Grosso G, Cobellis L, Raspagliesi F, di Re E: „Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases”, Gynecol Oncol 62, S. 360 - 365, 1996 [Reles`97]Reles A, Wein U, Lichtenegger W: „Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses”, J Clin Ultrasound 25, S. 217 - 25, 1997 [Ricke`03]Ricke J, Sehouli J, Hach C, Hanninen EL, Lichtenegger W, Felix R: „Prospectiv evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer”, Eur Radiol 13, S. 943 – 949, 2003 [Riman`98]Riman T, Persson I, Nilsson S: „Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence”, Clin Endocrinol 49, S. 695 - 707, 1998 [De Rosa`95]De Rosa V, di Mangoni S, Brunetti A, Caraco C, Graziano R, Gallo MS, Maffeo A: „Computed tomography and second-look surgery in ovarian cancer patients. Correlation, actual role and limitations of CT scan”, Eur J Gynecol Oncol 16, S. 123 - 129, 1995 [Rubin`91]Rubin SC, Hoskins WJ, Saigo PE, Chapman D, Hakes TB, Markman M, Reichman B, Almadrones L, Lewis JL: „Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy”, Gynecol Oncol 42, S. 137 - 141, 1991 [Rubin`99]Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ: „ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings”, Obstet Gynecol 93, S. 21 - 24, 1999 [Sakurai`02]Sakurai S, Shimizu Y, Utsugi K, Umezawa S, Kato T, Fukasawa I, Inaba N, Hasumi K: „Validity of complete paraaortic and pelvic lymphadenectomy in apparent stage I (pT1) ovarian carcinoma”, 38th ASCO Annual Meeting, Abstract: 801, 2002 [Scarabelli`95]Scarabelli C, Gallo A, Zarrelli A, Visentin C, Campagnutta E: „Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival”, Gynecol Oncol 56, S. 328 - 227, 1995 [Scharf`02]Scharf A, Günter HH, S Sohn: „Screening auf Ovarialkarzinom”, Der Gynäkologe 35, S. 537 - 547, 2002 [Schelling`01]Schelling M, de Waal JC: „Früherkennung”, in Kuhn: „Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge“, Tumorzentrum München, S. 10 - 13, 2001 [Schelling`01-1]Schelling M, de Waal JC: „Präoperative Diagnostik, Diagnosesicherung“, in Kuhn: „Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge“, Tumorzentrum München, S. 14 - 15, 2001 [Schildkraut`00]Schildkraut JM, Halabi S, Bastos E, Marchbanks PA, McDonald JA, Berchuck A: „Prognostic Factors in Early-Onset Epithelial Ovarian Cancer: A Population-Based Study“, Obstet Gynecol 95, S. 119 - 127, 2000 [Schmalfeldt`01]Schmalfeldt B, Diebold J, Harbeck N, Kuhn W, Nathrath W: „Prognosefaktoren”, in Kuhn: „Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge“, Tumorzentrum München, S. 21 - 23, 2001 [Schmidt-Matthiesen`02]Schmidt-Matthiesen H, Bastert G, Wallwiener D: „Gynäkologische Onkologie. Diagnostik, Therapie und Nachsorge auf der Basis der AGO-Leitlinien“, Schattauer Stuttgart New York, S. 73 – 96, 2002 [Schneider`98]Schneider D, Halperin R, Halperin D, Bukovsky I, Hadas E: „Prediction of the survival of patients with advanced ovarian cancer according to a risk model based on a scoring system“, Eur J Gynaecol Oncol 19, S. 547 - 552, 1998 [Schwartz`95]Schwartz PE, Chambers JT, Taylor KJ: „Early detection and screening for ovarian cancer”, J Cell Biochem Suppl 23, S. 233 - 237, 1995 [Scully`99]Scully RE, Sobin LH: „World Health Organisation (WHO). International histological classification of tumours. Histological typing of ovarian tumors”, Springer Berlin Heidelberg, 1999 [Scully`00]Scully RE: „Influence of origin of ovarian cancer on efficacy of screening“, The Lancet 355, S. 1028 – 1029, 2002 [Sehouli`01]Sehouli J: „Ovarialkarzinom First-line Therapie“, in Sehouli J, Lichtenegger W: „Chemotherapien in der Gynäkologischen Onkolgie“, Akademos, S. 59 - 68, 2001 [Sehouli’02]Sehouli J, Stengel D, Elling D, Ortmann O, Blohmer J, Riess H, Lichtenegger W: „First-Line Chemotherapy with Weekly Paclitaxel and Carboplatin for Advanced Ovarian Cancer: Phase I Study“, Gynecologic Oncology 85, S. 321 - 326, 2002 [Sehouli`02-1]Sehouli J, Stengel D, Drzewiecki K, Beldermann F, Camara O, Dari J et al.: „Weekly Taxol and Carboplatin as first-line Therapie in advanced ovarian cancer: a phase II-study”, 38th ASCO Annual Meeting, Abstract: 811, 2002 [Sehouli`02-2]Sehouli J, Lichtenegger W: „Neue Daten zum rezidivierten Ovarialkarzinom“, in Sehouli J, Lichtenegger W: „Chemotherapien in der Gynäkologischen Onkolgie“, Akademos, S. 109 - 115, 2002 [Sehouli`02-3]Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P, Lichtenegger W: „A Phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy“, Ann Oncol 13, S. 1749 - 1755, 2002 [Sehouli`03] Sehouli J, Akdogan Z, Heinze T, Konsgen D, Stengel D, Mustea A, Lichtenegger W: „Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study”, Anticancer Res 23, S. 1115-1118, 2003 [Sehouli`03-1]Sehouli J, Könsgen D, Klapp c, Walle U, Katsares I, Oskay G, Mustea A, Bühling K, Lichtenegger W: „Lebensqualität in der gynäkologischen Onkologie – Ein Bericht mit den Ergebnissen des ASCO-Meetings 2002“, Geburtsh Frauenheilk 63, S. 752 – 757, 2003 [Sehouli`03-2]Sehouli J, Könsgen D, Mustea A, Oskay-Özcelik G, Katsares I, Weidemann H, Lichtenegger W: „IMO – intraoperatives Mapping des Ovarialkarzinom“, Zentralbl Gynäkol 125, S. 129 – 135, 2003 [Sehouli`03-3]Sehouli J, Lichtenegger W: „Kommentar zur Publikation: International Collaborative Ovarian Neoplasm Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON 3 randomised trial. Lancet 2002 Aug 17; 360(9332):505-15”, Gyn 8, S. 196 -197, 2003 [Shimizu`98]Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG: „Toward the development of a universal grading system for ovarian epithelial carcinoma: Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up”, Cancer 82, S. 893 – 901, 1998 [Sliutz`96]Sliutz G: „Prognosefaktoren beim Ovarialkarzinom”, Wien-Med-Wochenschr. 146, S. 14 - 17, 1996 [Stadel`75]Stadel BV: „The etiology and prevention of ovarian cancer“, American Journal of Obstetrics and Gynecology 123, S. 772 – 774, 1975 [Stegner`96]Stegner HE: „Gynäkologie und Geburtshilfe”, Ferdinand Enke Verlag Stuttgart, 1996 [Stiff`00]Stiff PJ, Veum-Stone J, Lazarus HM, Ayash L, Edwards JR, Keating A, Klein JP, Oblon DJ, Shea TC, Thome S, Horowitz MM: „High-dose chemotherapy and autologous stemm-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report“, Ann Intern Med 133, S. 504 - 515, 2000 [Tattersall`02]Tattersall M: „Ovarian cancer chemotherapy: carboplatin as standard“, Lancet 360, S. 500 - 501, 2002 [Taylor`99]Taylor AE, Olver IN, Sivanthan T, Chi M, Purnell C: „Observer error in grading performance status in cancer patients“, Supportive Care in Cancer 7, S. 332 - 335, 1999 [Thigpen`93]Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, Williams S: „Age as prognostic factor in ovarian carcinoma”, Cancer 71, S. 606 - 614, 1993 [Thomssen`02]Thomssen C, Meier W: „Rezidivchirurgie beim Ovarialkarzinom. Indikationen und Möglichkeiten“, Der Onkologe 8, S. 1216 - 1221, 2002 [Trimble`01]Trimble EL: „Prospects for improving staging of ovarian cancers”, Lancet357, S. 159 - 160, 2001 [UICC`94]UICC, Hossfeld DK, Sherman CD, Love RR, Bosch FX: „Podrecznik onkologii klinicznej”, Wydawnictwo Naukowe PWN Warszawa Krakow, 1994 [UICC`97]UICC, Sobin LH, Wittekind C: „TNM Classification of malignant tumors”, Wiley-Liss New York, 1997 [Verres`92]Verres R: „Die Kunst zu leben. Krebsrisiko und Psyche“, Piper München Zurüch, 1992 [Wagner`01]Wagner U, Blohmer JU, Lück HJ: „Medikamentöse Rezidivtherapie“, Der Gynäkologe 34, S. 1020 - 1023, 2001 [West`97]West RJ, Zweig SF: „Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide”, Eur J Gynaecol Oncol 18, S. 343 - 348, 1997